Please login to the form below

Not currently logged in
Email:
Password:

Mark Booth joins Probiodrug

He becomes chief business officer

Probiodrug Mark BoothHalle, Germany-based Probiodrug has appointed Mark Booth as its chief business officer and member of its management board.

Booth joins the Alzheimer's disease specialty biopharmaceutical firm from Orexigen Therapeutics, where he served as chief commercial officer leading its business development and investor relations activities.

He brings over 30 years of biopharmaceutical experience to Probiodrug and has held key positions at Abbott Laboratories, Immunex Corporation and Takeda Pharmaceuticals, where he served as president of its North America operations.

Dr Erich Platzer, chairman of Probiodrug's supervisory board, said: “Mark's broad business background and proven track record make him a valuable addition to our management board.

“His extensive experience in business development and investor relations will be instrumental to propel Probiodrug's strategy internationally and in particular [in] the United States.”

Booth said: “This is truly a unique opportunity and I look forward to working with the team as we advance new and novel therapeutic treatments for Alzheimer's patients.”

31st March 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Rainmaker Healthcare Communications

Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics